remi barbier

Remi Barbier: The CEO Behind Cassava Sciences' Alzheimer's Gamble

By Christopher Rodriguez
AD

Remi Barbier is a biotech entrepreneur and executive whose name is closely tied to some of the most ambitious and controversial chapters in modern drug development. As the founder and longtime leader of Cassava Sciences, he steered a small pain-focused company into the high-stakes race to treat Alzheimer’s disease, capturing the attention of investors, scientists, and regulators alike. His career reflects both the immense promise and the unforgiving reality of bringing new medicines to market.

Barbier’s journey spans more than two decades of clinical setbacks, strategic pivots, and a fierce defense of his company’s science. From founding Pain Therapeutics in the late 1990s to championing the Alzheimer’s candidate simufilam, he has remained a polarizing figure—admired for his tenacity and criticized for the controversies that surrounded Cassava Sciences. Understanding his story offers a window into the risks, rewards, and reputational battles that define biotechnology leadership.

The Biotech Journey of Remi Barbier

Remi Barbier built his career at the intersection of science and business. He earned a B.A. in biology from the University of California, Berkeley, and an M.B.A. from the University of Chicago, giving him a foundation in both laboratory concepts and corporate strategy. In 1998, he founded Pain Therapeutics, a company focused on developing opioid painkillers with abuse-deterrent properties, a pressing need as the opioid crisis began to gain national attention.

AD
Home & Interior Archieven
Home & Interior Archieven
Phil Bernard Photographe Montréal-Blind Barber // Rennai Store at Royal Mount
Phil Bernard Photographe Montréal-Blind Barber // Rennai Store at Royal Mount
[Tournoi Maurice Revello] Des Français armés d’un beau potentiel
[Tournoi Maurice Revello] Des Français armés d’un beau potentiel

Pain Therapeutics went public in 2000, and Barbier served as its president, chief executive officer, and chairman. The company’s lead programs included Remoxy, an extended-release formulation of oxycodone designed to be difficult to crush, snort, or inject, and Oxytrex, a combination of oxycodone and naltrexone. Partnerships with larger pharmaceutical companies initially validated the approach, but regulatory hurdles and shifting market dynamics would soon test Barbier’s resolve.

Founding Pain Therapeutics

Pain Therapeutics aimed to solve a thorny problem: how to deliver effective pain relief while reducing the potential for abuse. Remoxy was the flagship candidate, and the company struck a partnership with King Pharmaceuticals, which was later acquired by Pfizer. The drug received multiple Complete Response Letters from the U.S. Food and Drug Administration, each time requiring additional studies or data. Despite these setbacks, Barbier continued to advocate for the program and kept the company afloat through difficult periods.

CUBVZ of Rémi Barbier
CUBVZ of Rémi Barbier
Rema | 424 Menswear Spring-Summer Fashion Show at Monnaie de Paris in Paris, France
Rema | 424 Menswear Spring-Summer Fashion Show at Monnaie de Paris in Paris, France
a drawing of two scissors and a spool of thread with leaves around it on a white background
a drawing of two scissors and a spool of thread with leaves around it on a white background

By the mid-2010s, Pfizer had returned the rights to Remoxy, and Pain Therapeutics faced dwindling resources and a beaten-down stock price. Rather than shutter the company, Barbier oversaw a dramatic strategic shift. This decision would ultimately transform Pain Therapeutics into Cassava Sciences and redirect its entire mission toward neurodegenerative disease, a move that few investors could have predicted.

Pivot to Cassava Sciences

In 2019, Pain Therapeutics was renamed Cassava Sciences, Inc., signaling a complete change in direction. The company abandoned its pain portfolio and focused on Alzheimer’s disease, a field notorious for high failure rates and decades of disappointing clinical trials. The new lead candidate was simufilam, an oral drug designed to bind to altered filamin A, a protein implicated in neuroinflammation and amyloid-beta signaling. Cassava also developed SavaDx, a diagnostic approach intended to detect Alzheimer’s-related changes in blood.

AD

The pivot was bold and risky. Cassava Sciences had no approved products and limited revenue, but Barbier argued that simufilam’s mechanism offered a fresh angle in a field dominated by antibody therapies. Early Phase 2 data suggested potential cognitive benefits, and the company’s share price began to climb. Investors who had written off Pain Therapeutics suddenly saw a new opportunity in the Alzheimer’s space, and Barbier became one of the most visible CEOs in neurodegeneration research.

a man holding a small child with his face close to the chest, while he is wearing
a man holding a small child with his face close to the chest, while he is wearing
gone more red Scene Dudes, Daniel Desario Hair, Scene Guy Style, Male Scene Style, Fallen 2016 Daniel, Emo Scene Hair Men, Emo Dude With Red Hair, 2000s Scene Men, Scene Hairstyles For Guys
gone more red Scene Dudes, Daniel Desario Hair, Scene Guy Style, Male Scene Style, Fallen 2016 Daniel, Emo Scene Hair Men, Emo Dude With Red Hair, 2000s Scene Men, Scene Hairstyles For Guys
Berber Shop, Barber Photography, Barber Shop Photography, Barber Photography Portraits, Barber Hairstyle Poster, Barber Photo, Barber Tools Photography, Barber Cover Photo, Barber Photoshoot Ideas
Berber Shop, Barber Photography, Barber Shop Photography, Barber Photography Portraits, Barber Hairstyle Poster, Barber Photo, Barber Tools Photography, Barber Cover Photo, Barber Photoshoot Ideas
Super Workshow! @delormecoiffure #mcb2017 #rémithorparis #homme #coiffeur #barbier #94 #esthetique #paris #barbe #coiffeurparis #barbe #barber #rémithorgrandparis #barbierctéteil #échat #barbier94 #créateurdebeauté #beautybuilder #man #visagiste #colorationbarbe #coloriste #igers #fashion #trend #tendance #coiffurehomme #barbershop Moustach' Barbershop Logo Design, Male Hairdresser Photoshoot, Barber Shave, Cedric The Entertainer Barbershop, Barber Haircut, Barbershop Paris, Retro Barber Tool Design, Barber Photo, Dapper Barber
Super Workshow! @delormecoiffure #mcb2017 #rémithorparis #homme #coiffeur #barbier #94 #esthetique #paris #barbe #coiffeurparis #barbe #barber #rémithorgrandparis #barbierctéteil #échat #barbier94 #créateurdebeauté #beautybuilder #man #visagiste #colorationbarbe #coloriste #igers #fashion #trend #tendance #coiffurehomme #barbershop Moustach' Barbershop Logo Design, Male Hairdresser Photoshoot, Barber Shave, Cedric The Entertainer Barbershop, Barber Haircut, Barbershop Paris, Retro Barber Tool Design, Barber Photo, Dapper Barber
Bantu Knots Hairstyles Ponytail, Bantu Knots With Curly Hair In The Back, Bantu Knots Ponytail, Bantu Knots With Ponytail, Bantu Knots Wig Hairstyles, Black Hairstyles Bantu Knots, Bantu Knots Hairstyles Wig, Bantu Knot Curls Short Hair, Bantu Knot Wig Hairstyle
Bantu Knots Hairstyles Ponytail, Bantu Knots With Curly Hair In The Back, Bantu Knots Ponytail, Bantu Knots With Ponytail, Bantu Knots Wig Hairstyles, Black Hairstyles Bantu Knots, Bantu Knots Hairstyles Wig, Bantu Knot Curls Short Hair, Bantu Knot Wig Hairstyle
Curly Heads Light Skins, Curly Hair Light Skin Girl, Cute Lightskinned Girl, Thick Light Skin Curly Hair, Pretty Light Skin Girls With Curly Hair, Light Skin 13 Girl, Light Skin Girls Pretty 13, Pretty Light Skin Girls 13, Brazil Curly Hair
Curly Heads Light Skins, Curly Hair Light Skin Girl, Cute Lightskinned Girl, Thick Light Skin Curly Hair, Pretty Light Skin Girls With Curly Hair, Light Skin 13 Girl, Light Skin Girls Pretty 13, Pretty Light Skin Girls 13, Brazil Curly Hair

Simufilam and the High-Stakes Alzheimer’s Race

Alzheimer’s disease has long been considered a graveyard for drug development, with countless candidates failing in late-stage trials. Cassava Sciences entered this arena with simufilam, positioning it as a small molecule that could modify the disease rather than simply treat symptoms. The company reported promising results from an open-label Phase 2b trial, showing improvements on cognitive scales over time. These findings generated intense excitement and propelled Cassava’s market valuation into the billions.

Barbier and his team planned two Phase 3 trials, RETHINK-ALZ and REFOCUS-ALZ, to confirm simufilam’s efficacy in larger, randomized populations. The trials were designed to measure changes in cognition and function over 52 weeks. For patients and families desperate for new options, Cassava’s program represented a rare source of hope. For investors, it was a binary bet: success could mean a breakthrough therapy, while failure could erase years of work and billions in value.

AD

Controversies and Scientific Scrutiny

As Cassava Sciences gained prominence, so did skepticism. In 2021, a citizen petition was filed with the FDA alleging data manipulation in some of the company’s published research. The petition, along with subsequent media reports, raised questions about the integrity of certain Western blot images and statistical analyses. Cassava Sciences strongly denied any wrongdoing, and Barbier publicly defended the company’s science, calling the allegations misleading and financially motivated.

Remi Labarre 🎨❤️
Remi Labarre 🎨❤️
Barber Cuts
Barber Cuts
Normal people Barber's
Normal people Barber's
Side Cornrows, Cornrow Braids Men, Braid Styles For Men, Boy Braids Hairstyles, Growing Healthy Hair, Guys Grooming, Cornrow Hairstyles For Men, Braids For Boys, Afro Men
Side Cornrows, Cornrow Braids Men, Braid Styles For Men, Boy Braids Hairstyles, Growing Healthy Hair, Guys Grooming, Cornrow Hairstyles For Men, Braids For Boys, Afro Men

The scrutiny intensified when the U.S. Securities and Exchange Commission and the Department of Justice launched investigations into the company. Cassava’s stock became extraordinarily volatile, swinging wildly on news of regulatory developments, short-seller reports, and scientific commentary. Barbier remained steadfast, often appearing in interviews and presentations to refute critics. The controversy split the scientific community, with some researchers calling for more transparency and others arguing that the attacks were impeding legitimate drug development.

Phase 3 Results and Leadership Transition

In November 2024, Cassava Sciences announced that the Phase 3 RETHINK-ALZ trial did not meet its primary endpoints. Simufilam failed to show a statistically significant benefit on measures of cognition and function compared to placebo. The news sent the company’s stock price plummeting and dealt a severe blow to the Alzheimer’s community. Shortly afterward, Cassava announced it would discontinue the second Phase 3 trial, REFOCUS-ALZ, based on the lack of efficacy observed in the first study.

AD

In January 2025, Remi Barbier retired from his roles as CEO and chairman of Cassava Sciences. The company appointed Richard “Rick” Barry as interim CEO and began exploring strategic alternatives. Barbier’s departure marked the end of an era for the company he founded and led for more than 25 years. While his tenure ended amid clinical failure and lingering controversy, his influence on the Alzheimer’s drug development landscape remains undeniable.

The story of Remi Barbier is a case study in biotech’s dual nature: bold vision paired with brutal uncertainty. He built companies from scratch, navigated public markets, and pursued a disease that has defeated some of the world’s largest pharmaceutical firms. Whether history remembers him as a pioneering entrepreneur or a cautionary tale depends largely on how the scientific community resolves the questions that surrounded simufilam. What is clear is that his journey underscores the need for rigorous data, transparent communication, and resilience in the face of overwhelming odds. As new Alzheimer’s therapies continue to emerge, the lessons from Barbier’s career will likely inform the next generation of biotech leaders who dare to take on the impossible.

AD